January 7th 2022
Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
January 5th 2022
Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.
Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.
Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.
December 22nd 2021
Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.
Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.
December 15th 2021
Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.
Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.
December 8th 2021
Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.
Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.
January 12th 2018
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).
May 8th 2017
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.
February 24th 2017
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).
November 26th 2014
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.
November 5th 2014
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.